Karen Wagner is a Managing Partner at Ysios Capital where she focuses on therapeutic investments.
Besides Vivet Therapeutics, Karen serves on the boards of Galecto, Aelix Therapeutics, Minoryx and Xeltis. Formerly she was a board member of Kala Pharmaceutics and Cardoz.
She holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.
Karen has over 20 years of experience in business development and financing in the biotech/pharma sector working for companies such as F. Hoffmann-La Roche and GlycArt. Previously she was a Consultant with McKinsey & Company’s Global Healthcare Practice.